Olaparib Plus Bevacizumab ICER Exceeds Standard Thresholds in HRD-Positive Ovarian Cancer
An economic evaluation of the PAOLA-1 trial finds that olaparib plus bevacizumab maintenance in HRD-positive ovarian cancer exceeds standard cost-effectiveness ...



















